What is the prevalence of Paroxysmal nocturnal hemoglobinuria?

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disease with an estimated global prevalence of 1 to 5 per million people. While exact figures vary due to historical underdiagnosis, the condition is considered ultra-rare and affects both males and females equally, typically manifesting in early to middle adulthood.

What is the estimated prevalence and incidence of Paroxysmal nocturnal hemoglobinuria?

The prevalence of Paroxysmal nocturnal hemoglobinuria is widely estimated to be between 1 and 5 per million individuals in the general population. Because Paroxysmal nocturnal hemoglobinuria is a rare condition, accurate global incidence rates are difficult to calculate; however, some literature suggests an incidence rate of approximately 1 to 2 new cases per million people per year. These figures are estimates and likely represent an undercount, as patients with mild or subclinical symptoms may remain undiagnosed for years. At DiseaseMaps.org, we currently support a community of 162 individuals living with Paroxysmal nocturnal hemoglobinuria, providing a vital real-world perspective on the patient experience that often transcends clinical statistics.

Who is most commonly affected by Paroxysmal nocturnal hemoglobinuria?

Paroxysmal nocturnal hemoglobinuria does not show a strong preference for a specific gender, affecting males and females with roughly equal frequency. Regarding age of onset, the condition is most commonly diagnosed in young adults, typically between the ages of 30 and 40, though it can occur at any age, including in childhood. While geographic and ethnic variations in the prevalence of Paroxysmal nocturnal hemoglobinuria are not definitively proven, some studies suggest that the condition may be more frequently identified in regions with higher rates of aplastic anemia, as the two conditions are closely linked pathologically.

Why is it difficult to determine the exact prevalence of Paroxysmal nocturnal hemoglobinuria?

Determining the precise number of people living with Paroxysmal nocturnal hemoglobinuria is challenging due to several clinical factors:

• Diagnostic Delays: Because Paroxysmal nocturnal hemoglobinuria is rare and symptoms can be non-specific (such as fatigue or dark urine), patients often consult multiple specialists before receiving a correct diagnosis.


• Underdiagnosis: Patients with small PNH clones may have few symptoms and may never be formally diagnosed or included in epidemiological registries.


• Misdiagnosis: The disease is frequently misdiagnosed as other blood disorders, such as aplastic anemia or myelodysplastic syndromes, leading to gaps in reporting.


• Evolution of Testing: The increasing availability of high-sensitivity flow cytometry has improved detection rates, meaning that modern prevalence estimates are often higher than those reported in older literature.

Next steps

• Consult a hematologist who specializes in bone marrow failure syndromes or complement-mediated disorders.


• Request a high-sensitivity flow cytometry test if you suspect you have symptoms related to Paroxysmal nocturnal hemoglobinuria.


• Join the DiseaseMaps.org community to connect with other patients and share experiences about navigating life with this rare condition.


• Inquire with your medical team about clinical trials or patient registries that track long-term outcomes for those with Paroxysmal nocturnal hemoglobinuria.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: Paroxysmal nocturnal hemoglobinuria (ORPHA:793).


• NIH Genetic and Rare Diseases Information Center (GARD): Paroxysmal nocturnal hemoglobinuria.


• OMIM (Online Mendelian Inheritance in Man): PIGA gene and PNH pathology.


• Aplastic Anemia & MDS International Foundation: PNH resources and clinical data.